352 related articles for article (PubMed ID: 19886071)
1. Phospholipase A2 in patients with noncardioembolic ischemic stroke and severe inflammatory reaction.
Cojocaru IM; Cojocaru M; Tănăsescu R; Iliescu I; Dumitrescu L; Burcin C; Gurban CV; Sfrijan F
Rom J Intern Med; 2009; 47(1):61-5. PubMed ID: 19886071
[TBL] [Abstract][Full Text] [Related]
2. [Does Lp-PLA2 determination help predict atherosclerosis and cardiocerebrovascular disease?].
Sertić J; Skorić B; Lovrić J; Bozina T; Reiner Z
Acta Med Croatica; 2010 Oct; 64(4):237-45. PubMed ID: 21688606
[TBL] [Abstract][Full Text] [Related]
3. Elevated Lp-PLA2 levels add prognostic information to the metabolic syndrome on incidence of cardiovascular events among middle-aged nondiabetic subjects.
Persson M; Hedblad B; Nelson JJ; Berglund G
Arterioscler Thromb Vasc Biol; 2007 Jun; 27(6):1411-6. PubMed ID: 17431184
[TBL] [Abstract][Full Text] [Related]
4. Oxidized phospholipids, lipoprotein(a), lipoprotein-associated phospholipase A2 activity, and 10-year cardiovascular outcomes: prospective results from the Bruneck study.
Kiechl S; Willeit J; Mayr M; Viehweider B; Oberhollenzer M; Kronenberg F; Wiedermann CJ; Oberthaler S; Xu Q; Witztum JL; Tsimikas S
Arterioscler Thromb Vasc Biol; 2007 Aug; 27(8):1788-95. PubMed ID: 17541022
[TBL] [Abstract][Full Text] [Related]
5. Prognostic utility of lipoprotein-associated phospholipase A2 for cardiovascular outcomes in patients with stable coronary artery disease.
Sabatine MS; Morrow DA; O'Donoghue M; Jablonksi KA; Rice MM; Solomon S; Rosenberg Y; Domanski MJ; Hsia J;
Arterioscler Thromb Vasc Biol; 2007 Nov; 27(11):2463-9. PubMed ID: 17766330
[TBL] [Abstract][Full Text] [Related]
6. [Lipoprotein-associated phospholipase A(2) and stroke].
Alvarez-Pérez FJ; Verde I
Rev Neurol; 2009 Jul 16-31; 49(2):88-94. PubMed ID: 19598138
[TBL] [Abstract][Full Text] [Related]
7. Interpretation of lipoprotein-associated phospholipase A2 levels is influenced by cardiac disease, comorbidities, extension of atherosclerosis and treatments.
Charniot JC; Khani-Bittar R; Albertini JP; Giral P; Cherfils C; Cosson C; Guillerm E; Leprince P; Gandjbakhch I; Bonnefont-Rousselot D
Int J Cardiol; 2013 Sep; 168(1):132-8. PubMed ID: 23103135
[TBL] [Abstract][Full Text] [Related]
8. Lipoprotein-associated phospholipase A2 during the hyperacute stage of ischemic and hemorrhagic strokes.
Rosso C; Rosenbaum D; Pires C; Cherfils C; Koujah N; Mestari F; Gillet E; Crozier S; Sahli-Amor M; Samson Y; Bonnefont-Rousselot D; Khani-Bittar R
J Stroke Cerebrovasc Dis; 2014 Apr; 23(4):e277-82. PubMed ID: 24513482
[TBL] [Abstract][Full Text] [Related]
9. Lipoprotein-associated phospholipase A2: an independent predictor of cardiovascular risk and a novel target for immunomodulation therapy.
Khakpour H; Frishman WH
Cardiol Rev; 2009; 17(5):222-9. PubMed ID: 19690473
[TBL] [Abstract][Full Text] [Related]
10. Lipoprotein-associated phospholipase A2: a new biomarker for cardiovascular risk assessment and potential therapeutic target.
Carlquist JF; Muhlestein JB; Anderson JL
Expert Rev Mol Diagn; 2007 Sep; 7(5):511-7. PubMed ID: 17892360
[TBL] [Abstract][Full Text] [Related]
11. Plasma Lp-PLA2 in acute coronary syndrome: association with major adverse cardiac events in a community-based cohort.
Li N; Li S; Yu C; Gu S
Postgrad Med; 2010 Jul; 122(4):200-5. PubMed ID: 20675983
[TBL] [Abstract][Full Text] [Related]
12. Lipoprotein phospholipase A2 mass and activity are not associated with the diagnosis of acute brain ischemia.
Tai W; Garcia M; Mlynash M; Kemp S; Albers GW; Olivot JM
Cerebrovasc Dis; 2014; 38(5):324-7. PubMed ID: 25428761
[TBL] [Abstract][Full Text] [Related]
13. Review of the evidence for the clinical utility of lipoprotein-associated phospholipase A2 as a cardiovascular risk marker.
Corson MA; Jones PH; Davidson MH
Am J Cardiol; 2008 Jun; 101(12A):41F-50F. PubMed ID: 18549871
[TBL] [Abstract][Full Text] [Related]
14. Utility of lipoprotein-associated phospholipase A2 for prediction of 30-day major adverse coronary event in patients with the first anterior ST-segment elevation myocardial infarction treated by primary percutaneous coronary intervention.
Stankovic S; Asanin M; Trifunovic D; Majkic-Singh N; Miljković A; Ignjatovic S; Mrdovic I; Matic D; Savic L; Ostojic M; Vasiljevic Z
Clin Lab; 2012; 58(11-12):1135-44. PubMed ID: 23289182
[TBL] [Abstract][Full Text] [Related]
15. Lipoprotein-associated phospholipase A2 and risk of stroke.
Gorelick PB
Am J Cardiol; 2008 Jun; 101(12A):34F-40F. PubMed ID: 18549870
[TBL] [Abstract][Full Text] [Related]
16. Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident ischemic stroke in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study.
Ballantyne CM; Hoogeveen RC; Bang H; Coresh J; Folsom AR; Chambless LE; Myerson M; Wu KK; Sharrett AR; Boerwinkle E
Arch Intern Med; 2005 Nov; 165(21):2479-84. PubMed ID: 16314544
[TBL] [Abstract][Full Text] [Related]
17. [Lipoprotein associated phospholipase A2].
Rubinstein A; Izkhakov E
Harefuah; 2011 Feb; 150(2):136-40, 205. PubMed ID: 22164942
[TBL] [Abstract][Full Text] [Related]
18. Local production of lipoprotein-associated phospholipase A2 and lysophosphatidylcholine in the coronary circulation: association with early coronary atherosclerosis and endothelial dysfunction in humans.
Lavi S; McConnell JP; Rihal CS; Prasad A; Mathew V; Lerman LO; Lerman A
Circulation; 2007 May; 115(21):2715-21. PubMed ID: 17502572
[TBL] [Abstract][Full Text] [Related]
19. Low basal levels of circulating adiponectin in patients undergoing coronary stenting predict in-stent restenosis, independently of basal levels of inflammatory markers: lipoprotein associated phospholipase A2, and myeloperoxidase.
Moldoveanu E; Mut-Vitcu B; Tanaseanu GR; Marta DS; Manea G; Kosaka T; Vidulescu C; Tanaseanu C
Clin Biochem; 2008 Dec; 41(18):1429-33. PubMed ID: 18930040
[TBL] [Abstract][Full Text] [Related]
20. Temporal profile and prognostic value of Lp-PLA2 mass and activity in the acute stroke setting.
Delgado P; Chacón P; Penalba A; Pelegrí D; Merino C; Ribó M; Rubiera M; Álvarez-Sabin J; Montaner J
Atherosclerosis; 2012 Feb; 220(2):532-6. PubMed ID: 22153151
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
